Articles
29 May 2009
Vol. 1 No. 4: Nordic von Willebrand Workshop 2004
https://doi.org/10.4081/hmr.v1i4.238

Current treatment indications for von Willebrand factor concentrate

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
213
Views
483
Downloads

Authors

Erik Berntorp
support@pagepress.org
Transfusion with blood products containing factor VIII/VWF complex is the treatment of choice for those patients (approx. 20%) who are unresponsive to DDAVP. In developed countries, virucidally treated concentrates of FVIII/VWF complex are today the mainstay of replacement therapy in von Willebrand’s disease (VWD). The treatment indication for von Willebrand factor (VWF) concentrate in an individual patient has to be judged in the light of the severity of the disease and the type of hemostatic challenge. DDAVP can be used in many cases in connection with e.g. minor surgery, whereas concentrate should be used in major surgery. Recent data shows that the rate of biologic response to DDAVP is relatively low, not only in type 2 but also in type 1 VWD (about 1/3), when uniform and stringent criteria for patient selection and responsiveness are applied.1

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Current treatment indications for von Willebrand factor concentrate. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 1(4). https://doi.org/10.4081/hmr.v1i4.238